Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Large Volume Increase – Should You Buy?

Fresenius SE & Co. (OTCMKTS:FSNUY) shares saw an uptick in trading volume on Thursday . Approximately 374,341 shares traded hands during mid-day trading, an increase of 144% from the previous session’s volume of 153,257 shares.The stock last traded at $13.76 and had previously closed at $13.59.

Wall Street Analyst Weigh In

A number of research firms have issued reports on FSNUY. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy”.

Fresenius SE & Co. Stock Performance

The company’s 50 day moving average price is $12.05 and its 200-day moving average price is $12.74. The stock has a market cap of $31.07 billion, a P/E ratio of 17.46 and a beta of 0.61. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.98 and a current ratio of 1.27.

Fresenius SE & Co. (OTCMKTS:FSNUY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.33%. The business had revenue of $6.91 billion for the quarter, compared to analysts’ expectations of $6.65 billion. Equities analysts forecast that Fresenius SE & Co. will post 1.08 EPS for the current fiscal year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.